1794-P: Successful Standardization of a Hyperglycemic Clamp Method across Multiple Clinical Centers in the Restoring Insulin Secretion (RISE) Study

In RISE, repeated measurements of β-cell function and insulin sensitivity were performed using a standardized hyperglycemic glucose clamp method. After in person training, clamps were performed at seven centers, in youth (Y) and adults (A) with impaired glucose tolerance (IGT) or early type 2 diabetes (T2D). The goal was to achieve and maintain a plasma glucose concentration of 200 mg/dL over 120 minutes using a priming bolus followed by a continuous infusion of 20% dextrose adjusted based on plasma glucose measured every 5 minutes. Guidance for achieving target glycemia was formalized using spreadsheet-based calculations for glucose boluses and infusion rate changes, using participant weight and the delta of glucose from 200 mg/dL. We evaluated the achieved bedside glucose relative to target as well as differences between the guidance and selected infusion rates. We also compared relevant subgroups. Data from 923 clamps performed on 379 participants (up to three clamps each) were examined. Overall mean ± SD plasma glucose 10 minutes after the glucose bolus was 189 ± 18 mg/dL. This was higher in Y vs. A (194 ± 20 vs. 188 ± 18, p Y p=0.05, IGT > T2D p Disclosure K.J. Mather: Research Support; Self; Abbott, Merck & Co., Inc., Novo Nordisk Inc., Sanofi. A.H. Tjaden: None. S.A. Arslanian: Research Support; Self; National Institutes of Health. Other Relationship; Self; AstraZeneca, Eli Lilly and Company, Novo Nordisk Inc. K. Utzschneider: Other Relationship; Self; Medtronic. S. Caprio: None. K. Utzschneider: Other Relationship; Self; Medtronic. K.M. Atkinson: None. M. Cree-Green: Advisory Panel; Self; Novo Nordisk Inc. K.J. Nadeau: None. T.A. Buchanan: None. S.E. Kahn: Advisory Panel; Self; Boehringer Ingelheim International GmbH, Eli Lilly and Company, Intarcia Therapeutics, Janssen Scientific Affairs, LLC., Merck & Co., Inc., Novo Nordisk A/S, Pfizer Inc. T. Consortium: None. Funding American Diabetes Association (1-14-RISE-01 to S.E.K.); National Institute of Diabetes and Digestive and Kidney Diseases